JNemchinova/iStock via Getty Images
- Zealand Pharma (OTCPK:ZLDPF) said that top-line phase 2 results of its GLP-1/GLP-2 receptor dual agonist dapiglutide show promise as a weight loss treatment.
- Data indicated that after 12 weeks, those on dapiglutide at 4 mg and 6 mg doses had a mean weight loss change from baseline of 2.9% and 4.3%, respectively, compared to 2.2% on placebo.
- Dapiglutide was determined to be safe and well tolerated in the mechanistic DREAM trial.
- The drug is also being investigated in an ongoing 13-week Phase 1b trial at significantly higher doses. Top-line results for that trial are expected in the second half of the year.
- If eventually approved, dapiglutide would likely compete against Novo Nordisk's (NVO) Wegovy (semaglutide) and Eli Lilly's (LLY) Zepbound (tirzepatide).